Wednesday, April 1, 2026 – Thursday, April 2 - Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a standard protocol and may undermine weight-loss results.
Wednesday, April 1, 2026 – Thursday, April 2 - Now Eli Lilly has an obesity pill, too.
On Wednesday, the FDA approved orforglipron, the agency announced. It will be sold as Foundayo, and Lilly said it plans to sell a ...
Wednesday, April 1, 2026 – Thursday, April 2 - While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
Tuesday, March 31, 2026 – Wednesday, April 1 - INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited.
Across 60 meta-analyses that assessed 116 non...
Tuesday, March 31, 2026 – TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for major adverse cardiovascular events, according to a study published online...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- The PREVENT-TAHA8 intracoronary stem cell trial from Iran was officially retracted by The BMJ, months after an expression of concern was first published.
Poor diet remains a leading contributor to ischemic heart disease, with...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)...
Tuesday, March 31, 2026 – Wednesday, April 1 - A nascent biotech in the suburbs of Denver has convinced investors to commit $100 million to develop an oral small molecule in one of the most competitive fields in drug development.
Ambrosia Biosciences snagged the ...